written on 11.04.2014

Daiichi Sankyo lays out road map for Ranbaxy deal with Sun


Daiichi Sankyo today released its road map for the $3.2 all-stock Ranbaxy deal with Sun Pharmaceutical and the mile markers it sees to completion. It also provides some idea for drugmakers with products facing Ranbaxy generics of how quickly its revamp by Sun might put them in peril.